Genetic contribution to multiple sclerosis risk among Ashkenazi Jews

BMC Medical Genetics

Jorge R Oksenberg¹  Sergio E Baranzini¹  Stephen L Hauser¹  Pierre-Antoine Gourraud¹  Jayaji M Moré¹  Lennox Din¹  Antoine Lizée¹  Lohith Madireddy¹  Takuya Matsushita²  Pouya Khankhanian¹ 

[1] Department of Neurology, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco 94158, CA, USA;Current address: Graduate School of Medical Sciences, Kyushu University School of Medicine, 3-1-1, Maidashi, Higashi-ku 812-8582, Fukuoka City, Japan

关键词: Population genetics;    Genome-wide association study;    Ashkenazi jews;    Multiple sclerosis;   

Others  :  1223199
DOI  :  10.1186/s12881-015-0201-2

 received in 2014-12-16, accepted in 2015-07-13,  发布年份 2015

【 摘 要 】

Background

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, with a strong genetic component. Over 100 genetic loci have been implicated in susceptibility to MS in European populations, the most prominent being the 15:01 allele of the HLA-DRB1 gene. The prevalence of MS is high in European populations including those of Ashkenazi origin, and low in African and Asian populations including those of Jewish origin.

Methods

Here we identified and extracted a total of 213 Ashkenazi MS cases and 546 ethnically matched healthy control individuals from two previous genome-wide case-control association analyses, and 72 trios (affected proband and two unaffected parents) from a previous genome-wide transmission disequilibrium association study, using genetic data to define Ashkenazi. We compared the pattern of genetic risk between Ashkenazi and non-Ashkenazi Europeans. We also sought to identify novel Ashkenazi-specific risk loci by performing association tests on the subset of Ashkenazi cases, controls, probands, and parents from each study.

Results

The HLA-DRB1*15:01 allele and the non-HLA risk alleles were present at relatively low frequencies among Ashkenazi and explained a smaller fraction of the population-level risk when compared to non-Ashkenazi Europeans. Alternative HLA susceptibility alleles were identified in an Ashkenazi-only association study, including HLA-A*68:02 and one or both genes in the HLA-B*38:01-HLA-C*12:03 haplotype. The genome-wide screen in Ashkenazi did not reveal any loci associated with MS risk.

Conclusion

These results suggest that genetic susceptibility to MS in Ashkenazi Jews has not been as well established as that of non-Ashkenazi Europeans. This implies value in studying large well-characterized Ashkenazi populations to accelerate gene discovery in complex genetic diseases.

【 授权许可】

   
2015 Khankhanian et al.

【 图 表 】

Fig 1.

Fig 2.

Fig 3.

Fig 4.

Fig 5.

Fig 6.

【 参考文献 】

• [1]Hauser SL, Goodin DS: Multiple Sclerosis and Other Demyelinating Diseases, 17th edition edn: McGraw Hill; 2010.
• [2]Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008; 71(2):129-135.
• [3]Sotgiu S, Pugliatti M, Sotgiu A, Sanna A, Rosati G. Does the “hygiene hypothesis” provide an explanation for the high prevalence of multiple sclerosis in Sardinia? Autoimmunity. 2003; 36(5):257-260.
• [4]Granieri E, Casetta I, Govoni V, Tola MR, Marchi D, Murgia SB, Ticca A, Pugliatti M, Murgia B, Rosati G. The increasing incidence and prevalence of MS in a Sardinian province. Neurology. 2000; 55(6):842-848.
• [5]Alter M, Kahana E, Zilber N, Miller A. Multiple sclerosis frequency in Israel’s diverse populations. Neurology. 2006; 66(7):1061-1066.
• [6]Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z et al.. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476(7359):214-219.
• [7]Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D et al.. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013; 45(11):1353-1360.
• [8]Atzmon G, Hao L, Pe’er I, Velez C, Pearlman A, Palamara PF, Morrow B, Friedman E, Oddoux C, Burns E et al.. Abraham’s children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. Am J Hum Genet. 2011; 86(6):850-859.
• [9]Behar DM, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J, Rootsi S, Chaubey G, Kutuev I, Yudkovsky G et al.. The genome-wide structure of the Jewish people. Nature. 2010; 466(7303):238-242.
• [10]Hammer MF, Redd AJ, Wood ET, Bonner MR, Jarjanazi H, Karafet T, Santachiara-Benerecetti S, Oppenheim A, Jobling MA, Jenkins T et al.. Jewish and Middle Eastern non-Jewish populations share a common pool of Y-chromosome biallelic haplotypes. Proc Natl Acad Sci U S A. 2000; 97(12):6769-6774.
• [11]Klitz W, Gragert L, Maiers M, Fernandez-Vina M, Ben-Naeh Y, Benedek G, Brautbar C, Israel S. Genetic differentiation of Jewish populations. Tissue Antigens. 2010; 76(6):442-458.
• [12]Carmi S, Hui KY, Kochav E, Liu X, Xue J, Grady F, Guha S, Upadhyay K, Ben-Avraham D, Mukherjee S et al.. Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nat Commun. 2014; 5:4835.
• [13]Kwon OJ, Karni A, Israel S, Brautbar C, Amar A, Meiner Z, Abramsky O, Karussis D. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol. 1999; 56(5):555-560.
• [14]Tang H, Peng J, Wang P, Risch NJ. Estimation of individual admixture: analytical and study design considerations. Genet Epidemiol. 2005; 28(4):289-301.
• [15]Karni A, Kahana E, Zilber N, Abramsky O, Alter M, Karussis D. The frequency of multiple sclerosis in Jewish and Arab populations in greater Jerusalem. Neuroepidemiology. 2003; 22(1):82-86.
• [16]Karni A, Kohn Y, Safirman C, Abramsky O, Barcellos L, Oksenberg JR, Kahana E, Karussis D, Chapman J, Brautbar C. Evidence for the genetic role of human leukocyte antigens in low frequency DRB1*1501 multiple sclerosis patients in Israel. Mult Scler. 1999; 5(6):410-415.
• [17]Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, Raj T, Gourraud PA, Stranger BE, Oksenberg J et al.. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet. 2013; 9(11):e1003926.
• [18]Amirzargar A, Mytilineos J, Yousefipour A, Farjadian S, Scherer S, Opelz G, Ghaderi A. HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. Eur J Immunogenet. 1998; 25(4):297-301.
• [19]Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 2012; 248(1):87-103.
• [20]Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L et al.. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet. 2004; 74(1):160-167.
• [21]Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR et al.. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009; 18(4):767-778.
• [22]Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ et al.. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007; 357(9):851-862.
• [23]Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW et al.. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005; 58(6):840-846.
• [24]Gusev A, Palamara PF, Aponte G, Zhuang Z, Darvasi A, Gregersen P, Pe’er I. The Architecture of Long-Range Haplotypes Shared within and across Populations. Mol Biol Evol. 2012; 29(2):473-86.
• [25]Need AC, Kasperaviciute D, Cirulli ET, Goldstein DB. A genome-wide genetic signature of Jewish ancestry perfectly separates individuals with and without full Jewish ancestry in a large random sample of European Americans. Genome Biol. 2009; 10(1):R7. BioMed Central Full Text
• [26]Nelson MR, Bryc K, King KS, Indap A, Boyko AR, Novembre J, Briley LP, Maruyama Y, Waterworth DM, Waeber G et al.. The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am J Hum Genet. 2008; 83(3):347-358.
• [27]Price AL, Butler J, Patterson N, Capelli C, Pascali VL, Scarnicci F, Ruiz-Linares A, Groop L, Saetta AA, Korkolopoulou P et al.. Discerning the ancestry of European Americans in genetic association studies. PLoS Genet. 2008; 4(1):e236.
• [28]Browning BL, Browning SR. A fast, powerful method for detecting identity by descent. Am J Hum Genet. 2011; 88(2):173-182.
• [29]Gower JC. Some distance properties of latent root and vector methods used in multivariate analysis. Biometrika. 1966; 53:325-328.
• [30]Hartigan JA. Clustering Algorithms. Wiley, New York; 1975.
• [31]Gourraud PA, McElroy J, Caillier SJ, Johnson BA, Santaniello A, Hauser SL, Oksenberg JR. Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol. 2011; 69(1):65-74.